Michal Nath Puri is CHRO at NovoCure Ltd (NVCR). They have made 5 open-market trades across 1 company since 2024, most recently 2026-11-02.
CIK 0001997032
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVCR | 202,567 | $3.0M |
Shares reported on the most recent Form 4, priced at the 2026-11-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCR | SELL | 2026-11-02 | 2026-11-04 | $13.24 | $9K | — | — | — |
| NVCR | SELL | 2026-03-04 | 2026-03-05 | $13.31 | $15K | -9.5% | -22.8% | +18.5% |
| NVCR | SELL | 2026-02-27 | 2026-03-03 | $13.66 | $20K | -8.5% | -20.0% | +25.6% |
| NVCR | SELL | 2025-02-27 | 2025-03-03 | $20.02 | $28K | +13.1% | +1.1% | -3.9% |
| NVCR | SELL | 2024-10-31 | 2024-11-04 | $15.79 | $13K | +2.3% | +80.5% | +46.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.